A little more than a month after completing its big asset swap with GlaxoSmithKline, Novartis CEO Joe Jimenez says he’s going back to the bargaining table to look for some bolt-on buyouts in the $2 billion to $5 billion range.

…read more

Source: With GSK swap behind it, Novartis scouts for $2B-$5B buyouts


0 No comments